Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Mar 7, 2025
Finance
Strategics back Trimtech’s protein cluster degraders with $31M: Finance Report
Pharma venture arms join founding investors CIC, DDF to back U.K. start-up; plus venture rounds for Garuda, Ataraxis and Callio, and Tenaya’s follow-on
BioCentury | Feb 20, 2025
Emerging Company Profile
Switch: Precision siRNA knockdown
San Francisco-based biotech is pursuing CNS diseases with three-stranded siRNAs that can target specific cell types within a tissue
BioCentury | Nov 6, 2024
Product Development
Alzheimer’s roundup: Clinical progress and setbacks at CTAD
Readouts showcase promise of Roche’s brainshuttle; plus mixed results from Lilly, Lexeo and Anavex
BioCentury | Nov 5, 2024
Product Development
Alzheimer insights: Anti-amyloid safety and tau takeaways, a BioCentury podcast
Plus: FDA & the election and state of play for China biotech
BioCentury | Nov 1, 2024
Product Development
A tau mAb has achieved target clearance in Alzheimer’s patients
While the Phase II data at CTAD cast doubt on UCB’s bepranemab, they represent a critical advance for the field
BioCentury | Jul 30, 2024
Product Development
Eisai’s new data provide insight into how to get the most out of anti-amyloid mAbs
Three-year Leqembi readout in tau subgroup may be most impressive amyloid mAb data to date
BioCentury | Jun 13, 2024
Regulation
The amyloid debate’s next phase: presymptomatic Alzheimer’s disease
FDA guidance suggests identifying asymptomatic patients via biomarkers. Could digital endpoints and patient-reported outcomes fill the gap?
BioCentury | Jun 7, 2024
Regulation
Lilly raises the bar in Alzheimer’s, but complicates path to approval
FDA’s questions for advisory committee center on patient subgroups, and whether and when to end amyloid mAb treatment
BioCentury | May 15, 2024
Discovery & Translation
Voyager’s journey to identify a new shuttle for bringing gene therapies into the brain
Biotech identifies ALPL as a cross-species cell surface receptor mediating BBB crossing of AAV capsid family
Items per page:
1 - 10 of 288